Oncology
1 drug is in development for Neoplasms by Site.
- Companies
- 1
- Clinical trials
- 11
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Neoplasms by Site pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| Taletrectinib | Nuvation Bio Inc. (NUVB) |
About this indication
Neoplasms by Site context
Oncology·MeSH: Neoplasms by Site (D009371)
Also known as: Neoplasm Site, Neoplasm Sites, Neoplasms by Sites
Prevalence
3358.2 / 100K
Incidence
1547.2 / 100K/yr
Frequently asked questions
How many drugs are in development for Neoplasms by Site?
BioSniper tracks 1 drug in development for Neoplasms by Site across 1 company.
How many clinical trials target Neoplasms by Site?
There are 11 clinical trials targeting Neoplasms by Site tracked by BioSniper.
What is the prevalence of Neoplasms by Site?
The estimated prevalence of Neoplasms by Site is approximately 3358.2 per 100,000 population.